AbbVie (ABBV) said Tuesday that the European Commission approved its therapy, Maviret, for the treatment of acute hepatitis C virus infection in adults and children aged three years and older.
The drugmaker said the approval was supported by phase 3 data showing that Maviret's eight-week treatment regimen was effective in patients with acute HCV infection.
The company said the approval makes Maviret the only therapy approved in the European Union for the treatment of both acute and chronic HCV infection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments